lncRNA TPRG1-AS1 Screened the Onset of Acute Coronary Syndromes and Predicted Severity and the Occurrence of MACE During Patients' Hospitalization
Fan Zhang,Wei Li,Yingying Zhang,Dong Wang,Jing Li,Chengpeng Li,Liqun He
DOI: https://doi.org/10.2147/jir.s435945
IF: 4.5
2023-11-18
Journal of Inflammation Research
Abstract:Fan Zhang, &ast Wei Li, &ast Yingying Zhang, Dong Wang, Jing Li, Chengpeng Li, Liqun He Department of Cardiology, Intervention Cardiology Center, Wuhan No.1 Hospital, Wuhan, 430022, People's Republic of China &astThese authors contributed equally to this work Correspondence: Liqun He, Department of Cardiology, Intervention Cardiology Center, Wuhan No.1 Hospital, No. 215, Zhongshan Avenue, Qiaokou District, Wuhan, 430022, People's Republic of China, Tel/Fax +86-027-85332105, Email Purpose: Acute coronary syndrome (ACS) is a common acute myocardial ischemia syndrome and is one of the death-related causes of cardiovascular diseases. Identifying biomarkers to indicate disease severity and predict the occurrence of major adverse cardiovascular events (MACE) would benefit the clinical prognosis of ACS. This study estimated the expression and significance of lncRNA TPRG1-AS1 in the onset and development of ACS, aiming to explore a novel biomarker for the diagnosis and prognosis of ACS. Patients and Methods: A total of 109 ACS patients and 66 patients who received coronary angiography and excluded ACS were enrolled in this study. TPRG1-AS1 in the serum of study subjects was analyzed by PCR. The significance of TPRG1-AS1 in screening ACS was evaluated by ROC analysis. The association of TPRG1-AS1 with the disease severity of ACS was assessed by Pearson correlation analysis with patients' clinicopathological features. The potential of TPRG1-AS1 in predicting the occurrence of MACE was assessed by logistic regression analysis. Results: Significant upregulation of TPRG1-AS1 was observed in ACS patients, which served as a risk factor for ACS and distinguish between ACS patients and the normal group. TPRG1-AS1 was positively correlated with Gensini score, cys-C, cTnI, and NT-proBNP levels of ACS patients, which indicate severe development of ACS. Additionally, increasing serum TPRG1-AS1 was associated with the high incidence of MACE during patients' hospitalization and was identified as a risk factor for MACE in ACS patients. Conclusion: Upregulated TPRG1-AS1 in ACS served as a diagnostic biomarker and predicted the severe development of patients. Keywords: cardiovascular disease, lncRNA, onset, inpatient MACE, severity Acute coronary syndrome (ACS) is a common cardiovascular disease with high incidence, many complications, and high mortality. Atherosclerosis is the pathological basis of ACS, where the plaque is invaded or ruptured leading to the formation of a thrombus in the lumen and causing the stenosis or occlusion of the coronary lumen. 1 With the aging of the population, ACS has become a major disease that followed malignant tumors and dramatically threatens human health. The diagnosis of ACS is mainly based on clinical symptoms, electrocardiogram findings, and levels of myocardial necrosis markers. 2 The severity of coronary artery disease needs to be evaluated by coronary angiography. There are various complications of ACS, such as arrhythmia, hypotensive shock, cardiogenic shock, heart failure, and other cardiac dysfunction induced by cardiac cell death, which promote disease development and increase severity. Severe complications would induce lung infections. However, the diagnosis of ACS and the evaluation of complications depend on contrast medium, which is unfriendly for allergy, hyperthyroidism, renal dysfunction, and other special patients, and the costs are relatively high. 3,4 Therefore, there is an urgent need to explore novel biomarkers to screen ACS and indicate disease severity. Non-coding RNAs (ncRNAs) have been widely reported to participate in the onset and development of cardiovascular diseases. ncRNAs would show differential expression under different pathological conditions. Long non-coding RNAs (lncRNAs) are critical members of ncRNAs with a length of over 200 nt. Previous studies have reported the role of lncRNA in cardiovascular diseases and identified a series of candidate lncRNA biomarkers for ACS. 5 A previous transcriptome study identified a number of dysregulated lncRNAs in coronary artery diseases (CAD), among which lncRNA TPRG1-AS1 (ENST00000444488.1) was found to discriminate CAD patients and diagnose the occurrence of acute myocardial infarction. 6 TPRG1-AS1 is the antisense RNA of TPRG1 located on chromosome 3. Additionally, TPRG1-AS1 was recently revealed to regulate vascular smooth muscle cells and further regulate atherogenesis. 7 TPRG1-AS1 was also identified as a prognostic biomarker of head and neck squamous cell carcinoma and promoted the development of human cancers. 8–10 Therefore, TPRG1-AS1 was speculated to be involved in the pathogen and development of ACS, which lacks conf -Abstract Truncated-
immunology